Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Lexicon Pharmaceuticals, Inc./ 4

SEC Filing · 4

Lexicon Pharmaceuticals, Inc.

LXRXNASDAQEQUITYCurrent

SEC Filing

Filed Jun 4, 2026Accepted Jun 4, 2026, 4:13 PM EDTCIK 1062822Accession 0001062822-26-000106
View company →Permanent SEC source ↗
Share

Company context

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications.

Current securities

LXRXNASDAQ · EQUITY · Current

Recent company filings

  1. EFFECT filingAug 14, 2026
  2. S-3 filingAug 6, 2026
  3. S-8 filingAug 6, 2026
  4. 10-Q filingAug 6, 2026
  5. Results of Operations and Financial ConditionAug 6, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗